Considering the upregulation of Delta-like protein 3 (DLL3) in NEPC cases as compared to CRPC-adenocarcinomas, a humanized DLL3 antibody has been exploited for therapeutic targeting of NEPC (2019, Puca et al., 2019; Thoma, 2019). Here, DLL3 is linked to adenocarcinoma.